
Heranba Inds Q4 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
See what Heranba Inds management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Heranba Inds management said on order book — free account, 30 seconds.
Capex plans
Track Heranba Inds — get its next earnings analysis in your feed
How does Heranba Inds rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Heranba Inds rank in Fertilizers & Agrochemicals?
Compare Heranba Inds against every Fertilizers & Agrochemicals company (Q4 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Heranba Inds's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q4 FY23 earnings call analysis →
- Q1 FY24 earnings call analysis →
- Q2 FY25 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q2 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
Others in Fertilizers & Agrochemicals this season
- Best Agrolife Ltd (Q2 FY27)
Revenue from operations for Q2 FY27 is ₹407 crore, reflecting a year-on-year decline of 21%. Key results statement takeaways from Best Agrolife Ltd's Q2 FY27 ea
- Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
- Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear